SG11201608657QA - Method of treating lung adenocarcinoma - Google Patents

Method of treating lung adenocarcinoma

Info

Publication number
SG11201608657QA
SG11201608657QA SG11201608657QA SG11201608657QA SG11201608657QA SG 11201608657Q A SG11201608657Q A SG 11201608657QA SG 11201608657Q A SG11201608657Q A SG 11201608657QA SG 11201608657Q A SG11201608657Q A SG 11201608657QA SG 11201608657Q A SG11201608657Q A SG 11201608657QA
Authority
SG
Singapore
Prior art keywords
lung adenocarcinoma
treating lung
treating
adenocarcinoma
lung
Prior art date
Application number
SG11201608657QA
Inventor
Dana T Aftab
Peiwen Yu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53055132&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201608657Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of SG11201608657QA publication Critical patent/SG11201608657QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
SG11201608657QA 2014-04-25 2015-04-27 Method of treating lung adenocarcinoma SG11201608657QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461984599P 2014-04-25 2014-04-25
PCT/US2015/027800 WO2015164869A1 (en) 2014-04-25 2015-04-27 Method of treating lung adenocarcinoma

Publications (1)

Publication Number Publication Date
SG11201608657QA true SG11201608657QA (en) 2016-11-29

Family

ID=53055132

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201608657QA SG11201608657QA (en) 2014-04-25 2015-04-27 Method of treating lung adenocarcinoma

Country Status (21)

Country Link
US (1) US20170042880A1 (en)
EP (2) EP3906921A1 (en)
JP (2) JP6696908B2 (en)
KR (1) KR102474701B1 (en)
CN (1) CN106488768A (en)
AR (1) AR100191A1 (en)
AU (1) AU2015249232B2 (en)
BR (1) BR112016024672A2 (en)
CA (1) CA2946416C (en)
DK (1) DK3134084T3 (en)
EA (1) EA035223B1 (en)
ES (1) ES2874875T3 (en)
HU (1) HUE054557T2 (en)
IL (1) IL248408B (en)
MX (1) MX2016013600A (en)
PL (1) PL3134084T3 (en)
PT (1) PT3134084T (en)
SG (1) SG11201608657QA (en)
TW (1) TWI724988B (en)
UA (1) UA121655C2 (en)
WO (1) WO2015164869A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029506B1 (en) 2011-05-02 2018-04-30 Экселиксис, Инк. Method of treating cancer and bone cancer pain
JP6666849B2 (en) 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド Administration of cabozantinib preparation
ES2929888T3 (en) 2014-07-31 2022-12-02 Exelixis Inc Procedure for preparing fluorine-18 labeled cabozantinib and its analogues
CA2957466C (en) 2014-08-05 2023-10-17 Exelixis, Inc. Drug combinations to treat multiple myeloma
US11141413B2 (en) 2016-04-15 2021-10-12 Exelixis, Inc. Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
CN107353246A (en) * 2016-12-27 2017-11-17 辅仁药业集团熙德隆肿瘤药品有限公司 It is a kind of to prepare the rich method for Buddhist nun of antineoplastic card
JP2020521440A (en) * 2017-05-31 2020-07-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Multiplex PCR detection of ALK, RET, and ROS fusions
CA3065560A1 (en) 2017-06-09 2018-12-13 Exelixis, Inc. Liquid dosage forms to treat cancer
CN107541550A (en) * 2017-08-21 2018-01-05 上海派森诺生物科技股份有限公司 People's ROS1 fusion detection methods
JP7279026B2 (en) * 2017-09-20 2023-05-22 メルサナ セラピューティクス インコーポレイテッド Compositions and methods for predicting response to NAPI2B-targeted therapy
SG11202006945PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
MA51679A (en) 2018-01-26 2020-12-02 Exelixis Inc COMPOUNDS INTENDED FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS
CA3088200A1 (en) 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
DE102020005002A1 (en) * 2020-08-17 2022-02-17 Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh Means for the therapy of tumor diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US5756696A (en) 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US5491224A (en) 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US20100143918A1 (en) 2007-01-19 2010-06-10 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2009051846A2 (en) 2007-10-18 2009-04-23 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2008083319A1 (en) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Solid state forms of enantiopure ilaprazole
KR20200137052A (en) * 2009-01-16 2020-12-08 엑셀리시스, 인코포레이티드 Malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
US9364477B2 (en) 2009-02-12 2016-06-14 Cell Signaling Technology, Inc. Mutant ROS expression in human cancer
TWI585088B (en) * 2012-06-04 2017-06-01 第一三共股份有限公司 Imidazo[1,2-b]pyridazine analogues as kinase inhibitors
EP2892532B1 (en) * 2012-09-07 2019-02-13 Exelixis, Inc. Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma

Also Published As

Publication number Publication date
EP3134084A1 (en) 2017-03-01
EA035223B1 (en) 2020-05-18
JP6696908B2 (en) 2020-05-20
IL248408A0 (en) 2016-11-30
AR100191A1 (en) 2016-09-14
EA201692150A1 (en) 2017-02-28
JP2017513908A (en) 2017-06-01
CN106488768A (en) 2017-03-08
PT3134084T (en) 2021-05-11
IL248408B (en) 2022-06-01
NZ725576A (en) 2021-03-26
CA2946416C (en) 2022-07-19
BR112016024672A2 (en) 2021-02-02
US20170042880A1 (en) 2017-02-16
EP3906921A1 (en) 2021-11-10
KR20160147934A (en) 2016-12-23
DK3134084T3 (en) 2021-05-03
TWI724988B (en) 2021-04-21
EP3134084B1 (en) 2021-03-17
CA2946416A1 (en) 2015-10-29
UA121655C2 (en) 2020-07-10
AU2015249232B2 (en) 2020-06-25
AU2015249232A1 (en) 2016-11-10
ES2874875T3 (en) 2021-11-05
JP2019189646A (en) 2019-10-31
TW201622723A (en) 2016-07-01
HUE054557T2 (en) 2021-09-28
WO2015164869A1 (en) 2015-10-29
MX2016013600A (en) 2017-04-27
KR102474701B1 (en) 2022-12-05
PL3134084T3 (en) 2021-09-27

Similar Documents

Publication Publication Date Title
HK1251409A1 (en) Methods of treating cancer
IL259783A (en) Methods of treatment of malignancies
ZA201804227B (en) Methods of treating cancer
IL248408A0 (en) Method of treating lung adenocarcinoma
GB201701673D0 (en) Methods of well treatment
HK1248552A1 (en) Method of treatment with tradipitant
SG10201801562PA (en) Combination method for treatment of cancer
NO20161459A1 (en) Method for treatment of underground reservoirs
IL255079A0 (en) Methods for treating lung cancer
GB201410116D0 (en) Method of treatment
GB201800441D0 (en) Method of authentication
GB201904142D0 (en) Improved method of FT-IMS
SG11201703184SA (en) A method of treatment
GB201416832D0 (en) Methods of treatment
HK1244692A1 (en) Methods of treating fibrosis
IL253028B (en) Method of treatment
GB201602802D0 (en) Method of treatment
GB201521886D0 (en) A method of treating a well
GB201510197D0 (en) Method of treating ovarian cancer
GB201512139D0 (en) Methods of treatment
GB201421982D0 (en) Method of treatment
GB201421980D0 (en) Method of treatment
GB201511017D0 (en) Method of treatment
GB201415331D0 (en) Method of treatment
GB201414780D0 (en) Method Of Treatment